{"id":"rph-104","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4650513","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, RPH-104 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"RPH-104 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:54.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07206043","phase":"PHASE1","title":"Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2024-12-03","conditions":"Healthy","enrollment":130},{"nctId":"NCT05190991","phase":"PHASE2","title":"Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever","status":"RECRUITING","sponsor":"R-Pharm International, LLC","startDate":"2021-10-05","conditions":"Familial Mediterranean Fever, FMF","enrollment":60},{"nctId":"NCT05092776","phase":"PHASE2","title":"Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm International, LLC","startDate":"2021-04-29","conditions":"Familial Mediterranean Fever, FMF","enrollment":84},{"nctId":"NCT05432960","phase":"PHASE3","title":"Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)","status":"WITHDRAWN","sponsor":"R-Pharm International, LLC","startDate":"2023-12","conditions":"Adult-Onset Still's Disease, AOSD","enrollment":""},{"nctId":"NCT04213274","phase":"PHASE2","title":"Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome","status":"WITHDRAWN","sponsor":"R-Pharm Overseas, Inc.","startDate":"2023-05","conditions":"Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)","enrollment":""},{"nctId":"NCT05107934","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis","status":"SUSPENDED","sponsor":"R-Pharm Overseas, Inc.","startDate":"2025-12","conditions":"Recurrent Pericarditis","enrollment":80},{"nctId":"NCT05673902","phase":"PHASE3","title":"Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm International, LLC","startDate":"2020-12-11","conditions":"Idiopathic Recurrent Pericarditis","enrollment":17},{"nctId":"NCT04463251","phase":"PHASE2","title":"Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction","status":"COMPLETED","sponsor":"R-Pharm Overseas, Inc.","startDate":"2020-12-07","conditions":"Acute ST Segment Elevation Myocardial Infarction","enrollment":102},{"nctId":"NCT04692766","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2020-02-12","conditions":"Pericarditis","enrollment":20},{"nctId":"NCT04067492","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2018-03-26","conditions":"Gout Attack","enrollment":47},{"nctId":"NCT04380519","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2020-04-23","conditions":"COVID-19","enrollment":372},{"nctId":"NCT02667639","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-01","conditions":"Healthy","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["goflikicept","Arcerix"],"phase":"phase_3","status":"active","brandName":"RPH-104","genericName":"RPH-104","companyName":"R-Pharm Overseas, Inc.","companyId":"r-pharm-overseas-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"RPH-104 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}